YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice
Metrics: PDF 2268 views | HTML 1319 views | ?
Nan Zhao1,*, Yousheng Mao2,*, Gaijing Han1, Qiang Ju1, Lanping Zhou1, Fang Liu1, Yang Xu1, Xiaohang Zhao1
1State Key Laboratory of Molecular Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2Department of Thoracic Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
*These authors have contributed equally to this work
Yang Xu, e-mail: firstname.lastname@example.org
Xiaohang Zhao, e-mail: email@example.com
Keywords: PARP, parthanatos, chemotherapy, esophageal cancer
Received: March 12, 2015 Accepted: June 02, 2015 Published: June 15, 2015
Here we demonstrated that sepantronium bromide (YM155), a survivin suppressant, inhibited esophageal squamous-cell carcinoma (ESCC) growth in mice bearing human ESCC xenografts without affecting body weight. In cell culture, YM155 decreased survivin levels and caused PARP-1 activation, poly-ADP polymer formation, and AIF translocation from the cytosol to the nucleus. Genetic knockdown of PARP-1 or AIF abrogated YM155-induced parthanatos cell death. Furthermore, FOS, JUN and c-MYC gene transcription, which is stimulated by activated PARP-1, was increased following YM155 treatment. Our data demonstrate that YM155 did not trigger apoptosis, but induced parthanatos, a cell death dependent on PARP-1 hyper-activation, and support clinical development of YM155 in ESCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.